Project Grant R01CA285369
Award Date
9/18/24
Completion Date
8/31/29
Dollars Obligated
$963K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Cancer Institute awarded a $317,420 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Calla Health Foundation, a for-profit, woman-owned small business, for the development and validation of a patient-ready device called the CallaScope. This innovative technology aims to transform provider-controlled speculum-based imaging in a clinic to a patient-controlled self-imaging procedure at home, enabling increased access to cervical cancer screening, diagnosis,...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
The National Cancer Institute (NCI) awarded a $328,822 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to Implenomics Llcs, a minority-owned, women-owned small business located in Marblehead, Massachusetts. The grant, effective September 20, 2024 through August 31, 2026, will fund the development and pilot testing of the Integrated Cancer Awareness Network (ICAN), an innovative mHealth platform. ICAN will provide cancer risk, symptom, and screening education to...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Argosmd, Inc. to develop a low-cost, non-invasive "Mini-Reflectance Confocal Microscope (Mini-RCM)" device for aiding skin cancer diagnosis and treatment. The goal is to create a portable, fast-imaging microscopy tool that can improve upon existing Reflectance Confocal Microscopy (RCM) technology, which is currently limited in adoption due to...
The National Cancer Institute (NCI) awarded a $632,300 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Carnegie Mellon University. The grant will fund the development of an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional subcellular detail. The goal is to study interactions between cancer and...
This Project Grant award from the National Cancer Institute (NCI), under the Federal Assistance Listings program CFDA 93.395 Cancer Treatment Research, provides $406,500.00 to support the development of a novel, low-cost, single-use trans-nasal cryotherapy device for esophageal cancer treatment in low-resource settings. The project aims to design and validate a functional prototype of this first-of-its-kind device, which would enable unsedated cryoablation procedures to be administered through...
The National Cancer Institute (NCI) awarded a $164,639 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Brown University to develop a novel pipeline for kidney segmentation and registration based on deep learning techniques. The goal is to improve treatment efficacy and reduce recurrence rates for image-guided thermal ablation (IGTA), a minimally invasive cancer treatment. Specifically, the research will focus on detecting and mitigating potentially undetected...
The National Cancer Institute (NCI) awarded a 5-year, $706,365 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to The Trustees of Columbia University in the City of New York to implement the WHO-endorsed "screen, triage, and treat" (ISTAR) approach for cervical cancer screening among women living with HIV in La Romana, Dominican Republic. The project aims to sustain implementation of the ISTAR approach and generate new data to inform effective and equitable...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...
The National Cancer Institute (NCI) awarded a $1,729,890 Cooperative Agreement (CFDA 93.395 - Cancer Treatment Research) to Washington University to develop and validate a new 3D skin imaging technology, SkinScan3D, for improved monitoring of Kaposi Sarcoma (KS) treatment response in East Africa. The project has three main components: Refining the SkinScan3D device and usage protocols through human-centered design workshops with clinicians and patients in Uganda and Kenya to ensure the...